Also, given that altered IP3/calcium signaling is known to associate with ataxia, the identification of INPP5A as the primary molecule involved in the selective neurodegeneration in SCA17 provides a promising therapeutic target for the treatment of SCA17 and perhaps other diseases with ataxia as well. This evidence concerns the gene INPP5A and spinocerebellar ataxia type 17.